Exploring QSAR and pharmacophore mapping of structurally diverse selective matrix metalloproteinase-2 inhibitors

被引:30
作者
Halder, Amit Kumar [1 ]
Saha, Achintya [2 ]
Jha, Tarun [1 ]
机构
[1] Jadavpur Univ, Dept Pharmaceut Technol, Div Med & Pharmaceut Chem, Nat Sci Lab, Kolkata 700032, India
[2] Univ Calcutta, Dept Chem Technol, Kolkata, India
关键词
matrix-metalloproteinase-2; pharmacophore mapping; recursive partitioning; 2D QSAR; 3D QSAR; PYRROLIDINE DERIVATIVES; DESIGN; CORRELATE; CANCER; MMPS;
D O I
10.1111/jphp.12133
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives and Methods Matrix metalloproteinase-2 (MMP-2) is a potential target in metastases. Regression (conventional 2D QSAR) and classification (recursive partitioning (RP), Bayesian modelling) QSAR, pharmacophore mapping and 3D QSAR (comparative molecular field analysis and comparative molecular similarity analysis) were performed on 202 MMP-2 inhibitors. Key findings Quality of the regression models was justified by internal (Q(2)) and external (R-Pred(2)) cross-validation parameters. Stepwise regression was used to develop linear model (Q(2) = 0.822, R-Pred(2) = 0.667). Genetic algorithm developed linear (Q(2) = 0.845, R-Pred(2) = 0.638) and spline model (Q(2) = 0.882, R-Pred(2) = 0.644). The RP and Bayesian models showed cross-validated area under receiver operating characteristic curve (AUC(ROC_CV)) of 0.805 and 0.979 respectively. QSAR models depicted importance of descriptors like five-membered rings, fractional positively charged surface area, lipophilocity and so on. Higher molecular volume was found to be detrimental. Pharmacophore mapping was performed with two tools - Hypogen and PHASE. Both models indicated that one hydrophobic and three hydrogen bond acceptor features are essential. The Pharmacophore-aligned structures were used for CoMFA (Q(2) of 0.586 and R-Pred(2) of 0.689) and CoMSIA (Q(2) of 0.673 and R-Pred(2) of 0.758), results of which complied with the other analyses. Conclusions All modelling techniques were compared to each other. The current study may help in designing novel MMP-2 inhibitors.
引用
收藏
页码:1541 / 1554
页数:14
相关论文
共 48 条
[31]   Matrix metalloproteinase inhibitors as anticancer therapeutics [J].
Mannello, F ;
Tonti, G ;
Papa, S .
CURRENT CANCER DRUG TARGETS, 2005, 5 (04) :285-298
[32]   MMPs inhibitors: New succinylhydroxamates with selective inhibition of MMP-2 over MMP-3 [J].
Marcq, V ;
Mirand, C ;
Decarme, M ;
Emonard, H ;
Hornebeck, W .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (17) :2843-2846
[33]  
Matter H, 2004, CURR OPIN DRUG DISC, V7, P513
[34]   Matrix metalloproteinases [J].
Nagase, H ;
Woessner, JF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (31) :21491-21494
[35]   Chemometric modeling, docking and in silico design of triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors as antimalarials [J].
Ojha, Probir Kumar ;
Roy, Kunal .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2010, 45 (10) :4645-4656
[36]  
Panda P., 2007, Internet Elect. J. Mol. Des, V6, P280
[37]   Global Bayesian Models for the Prioritization of Antitubercular Agents [J].
Prathipati, Philip ;
Ma, Ngai Ling ;
Keller, Thomas H. .
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2008, 48 (12) :2362-2370
[38]   APPLICATION OF GENETIC FUNCTION APPROXIMATION TO QUANTITATIVE STRUCTURE-ACTIVITY-RELATIONSHIPS AND QUANTITATIVE STRUCTURE-PROPERTY RELATIONSHIPS [J].
ROGERS, D ;
HOPFINGER, AJ .
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 1994, 34 (04) :854-866
[39]  
Roy K, 2001, Drug Des Discov, V17, P315
[40]   Exploring QSAR and QAAR for inhibitors of cytochrome P450 2A6 and 2A5 enzymes using GFA and G/PLS techniques [J].
Roy, Kunal ;
Roy, Partha Pratim .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2009, 44 (05) :1941-1951